XELJANZ inhibits the effects of pro-inflammatory cytokines through intracellular targeting of the JAK pathway³

• XELJANZ works inside the cell to inhibit inflammation by blocking JAK-dependent signalling pathways⁴
• This reduces the production of multiple pro-inflammatory cytokines^4,5

Please refer to the SmPC before prescribing XELJANZ. Please click here to be directed to the SmPC.

XELJANZ in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs. XELJANZ can be given as monotherapy in case of intolerance to methotrexate (MTX) or when treatment with MTX is inappropriate.¹

XELJANZ in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.¹

XELJANZ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.¹ 

XELJANZ is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.¹

XELJANZ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs.¹

Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information